Funding for this research was provided by:
Global Stem cell Technology
Received: 19 October 2020
Accepted: 14 June 2021
First Online: 13 July 2021
: The different animal studies (approval number EC: 2019_003 and 2019_006) and the blood collection of the donor horses (approval number: EC_2016_003) were approved by the ethics committee of Global Stem cell Technology. The ethics committee is approved by the Flemish Government with permit LA1700607. The study was Good Clinical Practice compliant (VICH GL9), and all animal handlings were conducted according to European, national and regional animal welfare regulations (Directive 2001/82/EC as amended, Belgian animal welfare legislation (KB 29/05/2013), Directive 2010/63/EU and EMEA/CVMP/816/00-Final).
: Not applicable.
: Jan H. Spaas is employed by Boehringer Ingelheim, and Charlotte Beerts, ED, GP and LT are all employed by GST. Jan H. Spaas is an inventor of a pending patent covering the described immunomodulating technology owned by GST (EP19162270.3). EDP, Charlotte Beerts and Jan H. Spaas are the inventors of a patent covering the <sup>99m</sup>Tc labelling of ePB-MSCs owned by GST (EP19200152.7). The content of this manuscript contains a stem cell product under development owned by GST. The other authors declare that they have no competing interests.